ClinicalTrials.gg
RecruitingNCT05945329STANCEUpdated Sep 25, 2026

Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation

An interventional study of GalaFLEX LITE™ Scaffold and Standard surgery in Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III and Capsular Contracture Grade IV, sponsored by C. R. Bard. Recruiting at 37 sites in United States. Open to female participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by C. R. Bard (part of Becton, Dickinson and Company) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
22 Years to 70 Years
Sex
Female
01

Study summary

Prospective, randomized, controlled study to assess the safety and effectiveness of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and/or malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Subjects will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). This study is designed using an adaptive approach. The number of the treated breasts will range between 250 and 530.

Read the detailed description

Capsular contracture is the number one complication leading to revision surgery after breast augmentation(2-4) which has been commonly cited as impacting 10 to 20% of all breast augmentation patients.(5-10) A prospective, randomized controlled study of patients presenting with Baker grade III or IV capsular contracture will be undertaken to investigate the ability of P4HB (specifically GalaFLEX LITE™ Scaffold) to reduce the recurrence of clinically significant CC and/or malposition requiring surgical correction. The primary endpoint is a composite of capsular contracture recurrence and/or breast implant malposition recommended for surgery OR breast infections requiring oral or IV antibiotic treatment within 90 days of surgery and/or peri-implant fluid collection needing a drainage procedure within 10-90 days of surgery.

02

Conditions studied

  • Capsular Contracture Associated With Breast Implant
  • Capsular Contracture Grade III
  • Capsular Contracture Grade IV

Browse trials for

03

In context

Contracture

79 studies on the registry are indexed under Contracture; 18 are open to participants now.

This study's planned enrollment of 250 is above the median of 33 across 62 interventional studies indexed under Contracture.

Browse Contracture studies →

Lead sponsor

C. R. Bard is the lead sponsor of 117 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 13 (76%) have results posted.

First submitted after C. R. Bard became part of Becton, Dickinson and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Genetically female ≥22 and ≤70 years of age;
  2. Breast augmentation subject with capsular contracture (Baker grade III or IV);
  3. Desires a new silicone implant with no more than a ± 150cc volume change in implant size;
  4. Planned revision approach via inframammary fold (IMF) incision;
  5. Willing and able to comply with the study procedures including the 2-year follow-up visit;
  6. Can complete all required study visits as scheduled (i.e., physically attend);
  7. Has reviewed and completed an FDA required Breast Implant Patient Decision Checklist (e.g., implant-specific provided by the manufacturer);
  8. Has compatible smart technology that can be used for downloading/using the electronic patient diary; and,
  9. Provision of signed and dated form.

Exclusion criteria

Exclusion Criteria:

  1. \<18 or >35
  2. Existing and/or replacement implant size > 800 cc
  3. Has an extra-capsular silicone breast implant rupture where silicone gel has leaked outside of the capsule) in breast(s) intended for treatment
  4. Has prior use of a matrix (synthetic or biologic) in the breast(s) intended for treatment
  5. Abnormal breast findings on imaging within 1-year prior to randomization that have not been determined to be benign
  6. Subject reported current, or prior history of, Systemic Symptoms Associated with Breast Implants (SSBI - formerly referred to as BII (Breast Implant Illness))
  7. Infection present in the study breast(s) (day of index procedure (surgery) exclusions)
  8. Current or recent breastfeeding (within 3-months of enrollment) or history of mastitis within the 6-months prior to enrollment
  9. Prior or current diagnosis of breast cancer
  10. Has a mass that was palpated and has not been determined benign via acceptable imaging (MRI) or results
  11. Has undergone prior chest radiation treatment
  12. Has received chemotherapy within the last 12 months
  13. Current or recent (within 1-year of enrollment) alcohol/substance abuse
  14. Current or recent (within 4-weeks of enrollment) nicotine user (includes cigarettes, vaping, patches, gum, etc.)
  15. History of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIAALCL) or Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC)
  16. Planned use of any other matrix (synthetic, biosynthetic, or biological) in the study breast(s) other than the GalaFLEX LITE™ Scaffold used to fully wrap the implant
  17. Planned (within the 2-year follow-up time period) use of medical (e.g. montelukast/Singulair; zafirlukast/Accolate), physical (e.g. massage), or device assisted (e.g. mechanical/thermal ultrasound) tools to manage the breast capsule(s)
  18. Any medical condition that, in the opinion of the investigator, may be associated with unduly high risk of intra- or post-operative complications (e.g., insulin dependent diabetes, disease, connective tissue disorder, chronic lung or severe cardiovascular disease)
  19. Concurrent or planned use (within the 2-year follow-up time period) of autologous fat transfer in the study breast(s)
  20. Planned (within the 2-year follow-up time period) elective cosmetic surgery on the study breast(s) (e.g., staged mastopexy; revision for implant size change)
  21. Currently enrolled or has plans to enroll in another interventional clinical study that would interfere with this study
  22. Is pregnant or plans to become pregnant during the study period
  23. Known allergy to tetracycline hydrochloride and/or kanamycin sulfate
  24. Any condition that, in the Investigator's opinion, would preclude the use of the study device, interfere with the evaluation of the device or breast related outcomes
  25. Subject will not remain under the care of the investigator for all breast related plastic surgery procedures while enrolled in the study
  26. Actively using such as oral or biological therapies (inhalers or topical steroids are permitted)
  27. Confirmed diagnosis of the following rheumatic diseases or syndromes: systemic lupus erythematosus, Sjorgren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome
  28. Has, in the investigator's opinion, a mental illness or disability that would preclude their participation in the study
  29. Subject has an implant that was never commercially available in the United States
  30. Has been implanted with any silicone implant other than breast implants
  31. Is taking any drugs that would interfere with blood clotting or might result in elevated risk of significant postoperative complications (e.g., anticoagulants or antiplatelet medications such as Xarelto, Aspirin, or Eliquis. NSAIDs such as Celebrex, Ibuprofen, Meloxicam are not exclusionary).
  32. Works for Sponsor or any of their subsidiaries, the study surgeon, or is helping to conduct the study or are directly related to anyone that works for BD or any of their subsidiaries or the study surgeons
  33. Subjects planning to undergo significant weight loss utilizing surgical intervention or prescribed medication(s) (e.g., gastric bypass; gastric sleeve; GLP1 agonists). Subjects with stable weight after previous surgery or current GLP-1 agonists use are not excluded.

Day of Index Procedure (Surgery) Exclusion Criteria

  1. Has an extra-capsular rupture (breast implant silicone gel has leaked outside of the capsule) in breast(s) intended for treatment
  2. Suspicions of cancer from intraoperative capsule appearance such as capsule masses (based on surgical opinion/visual findings; does not require definitive pathology) inclusive of both BIA-ALCL and BIA-SCC; or,
  3. Presence of a systemic infection, infection at the surgical site, or infection anywhere in the body at the time of surgery.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    GalaFlex Light Scaffold

    Surgery performed with GalaFlex Lite Scaffold.

    Device: GalaFLEX LITE™ Scaffold

  • Active comparator
    Standard Surgery

    Surgery performed using standard surgical procedures with no scaffold.

    Other: Standard surgery

Interventions

  • DeviceGalaFLEX LITE™ Scaffold

    Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue

  • OtherStandard surgery

    Surgery performed without the use of a scaffold

06

What researchers measure

Primary outcomes

  1. Effectiveness of GalaFLEX LITE™ Scaffold for the stabilization of the implant pocket

    Composite of Recurrent Capsular Contracture Baker grade III/IV and/or breast implant malposition

    Time frame: 24-months after index surgery

Secondary outcomes

  1. Patient quality of life and satisfaction (12-month)

    Select Breast-Q© modules (standardized patient survey) for the treated breast(s): psychosocial wellbeing; sexual wellbeing; satisfaction with breasts; and physical wellbeing - chest

    Time frame: 12-months after index surgery

  2. Patient quality of life and satisfaction

    Select Breast-Q© modules (standardized patient survey) for the treated breast(s): psychosocial wellbeing; sexual wellbeing; satisfaction with breasts; and physical wellbeing - chest

    Time frame: 24-months after index surgery

  3. Safety of GalaFLEX LITE™ Scaffold for the stabilization of the implant pocket, reduction of capsular contracture recurrence, and/or malposition

    The occurrence of: * Breast fluid collection requiring a drainage procedure at any time, or after drain removal if one is used, within 90 days of surgery * Breast infection requiring oral (PO) or intravenous (IV) antibiotics related to the contracture revision surgery within 90 days of surgery

    Time frame: 90 days

Other outcomes

  1. Device or procedure related adverse events

    Select adverse events including: breast infection requiring PO or IV antibiotics related to the revision surgery; breast fluid collection requiring a drainage procedure; breast implant loss; any unscheduled/unanticipated breast reoperation; breast implant malposition recommended for surgery; skin necrosis; wound dehiscence; any seroma within 90 days of surgery; any hematoma within 90 days of surgery; capsular contracture Baker Grade \>1; and red breast syndrome

    Time frame: 24-months after index surgery

07

Study locations

33 of 37 sites recruiting
  • Defyne MD
    Scottsdale, Arizona 82521, United States
    Recruiting
    • Amy Norzagaray · Contactmanager@defynemd.com · 480-561-6185
    • Oren Tessler · Principal investigator
  • The Practice Plastic Surgery
    Beverly Hills, California 90210, United States
    Recruiting
    • Star Skillens · Contactstar@thepracticeps.com · 310 278-8200
    • Kelly Killeen, MD, FACS · Principal investigator
  • California Aesthetic Center
    Huntington Beach, California 92647, United States
    Recruiting
    • Tracy Bui-Vu · Contacttracy@stevevumd.com · (714) 848-1133
    • Steve Vu · Principal investigator
  • Donald S Mowlds, MD A Professional Corporation
    Newport Beach, California 92660, United States
    Recruiting
  • Newport Plastic and Reconstructive Surgery Associates
    Newport Beach, California 92660, United States
    Recruiting
  • Stewart Wang MD Inc.
    Pasadena, California 91101, United States
    Recruiting
  • Charlie Chen MD., Corp
    San Diego, California 92107, United States
    Recruiting
  • Tim Sayed MD
    San Diego, California 92121, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Beauty by Buford
    Lone Tree, Colorado 80124, United States
    Recruiting
  • Sanctuary Plastic Surgery
    Boca Raton, Florida 33431, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Careaga Plastic Surgery
    Miami, Florida 33134, United States
    Recruiting
  • Aesthetic Enhancements Plastic Surgery
    Orlando, Florida 32819, United States
    Recruiting
  • Scazorla Plastic Surgery
    Orlando, Florida 32827, United States
    Recruiting
  • Billington Plastic Surgery
    St. Petersburg, Florida 33710, United States
    Recruiting
  • VIVIFY Plastic Surgery
    Tampa, Florida 33606, United States
    Recruiting
    • Marlie Marino · ContactMarlie@vivifyps.com · 386-986-7010
    • Dallas Buchanan, MD · Principal investigator
  • The Graivier Center
    Alpharetta, Georgia 30005, United States
    Recruiting
  • Monarch Plastic Surgery and Skin Renewal Center
    Atlanta, Georgia 30328, United States
    Recruiting
    • Ashlee Kenny · Contactashlee@monarchga.com · 404-250-3333
    • Carmen Kavali · Principal investigator
  • Iteld Plastic Surgery
    Chicago, Illinois 60642, United States
    Recruiting
    • Kimmy Vu · Contactkimmy@driteld.com · 3127574505
    • Lawrence Iteld, MD · Principal investigator
  • Meridian Plastic Surgery Center
    Indianapolis, Indiana 46290, United States
    Recruiting
  • Northshore Plastic Surgery
    Mandeville, Louisiana 70448, United States
    Recruiting
    • Erin Peak · Contacterin@drboudreaux.com · 985-237-6050
    • Jeffrey Claiborne · Principal investigator
  • The Washington University
    St Louis, Missouri 63110, United States
    Recruiting
    • Jeremy Eisele · Contactjeisele@wustl.edu · 314-362-4639
    • Justin Sacks · Principal investigator
  • Reno Tahoe Plastic Surgery
    Reno, Nevada 89511, United States
    Recruiting
    • Erika Jolley · Contacterika@drmccormack.com · 775-284-2020
    • Tiffany McCormack, MD · Principal investigator
  • VIP Plastic Surgery
    West Long Branch, New Jersey 07764, United States
    Recruiting
    • Paige Dalton · Contactpaige@doctorvnj.com · 7329630809
    • Rahul Vemula · Principal investigator
  • Luxurgery
    New York, New York 10021, United States
    Recruiting
    • Christina Uong · Contactcku@luxurgery.com · 212-508-0000
    • Sachin Shridharani, MD · Principal investigator
  • Plastic Surgery Institute of New York
    New York, New York 10036, United States
    Recruiting
  • H/K/B Surgery
    Huntersville, North Carolina 28078, United States
    Recruiting
    • Devin White · ContactDevin@hkbsurgery.com · 704-659-2529
    • Bill Kortesis, MD, FACS · Principal investigator
  • Essential Medical Research
    Tulsa, Oklahoma 74137, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Pittsburgh Center for Plastic Surgery
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • The Plastic Surgery Center of Nashville With HKB
    Nashville, Tennessee 37203, United States
    Recruiting
  • Farah Naz Khan
    Dallas, Texas 75219, United States
    Recruiting
  • Southwest Plastic Surgery
    El Paso, Texas 79936, United States
    Recruiting
  • Aesthetic Center for Plastic Surgery
    Houston, Texas 77024, United States
    Recruiting
  • Hill Country Plastic Surgery
    San Antonio, Texas 78257, United States
    Recruiting
  • Next Stage Clinical Research
    San Antonio, Texas 78258, United States
    Terminated

    Not enrolling at this site — choose another above.

  • The Plastics Clinic
    Draper, Utah 84020, United States
    Recruiting
  • Athenix Advanced Plastic Surgery & Aesthetic Center
    Seattle, Washington 98005, United States
    Recruiting
  • Allen Gabriel MD
    Vancouver, Washington 98660, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Newport Plastic and Reconstructive Surgery Associates · Newport Beach, United StatesContact l•••@newportplastic.com · •••1502→c•••@newportplastic.com · •••1502
  • Charlie Chen MD., Corp · San Diego, United StatesContact b•••@me.com · •••1538→i•••@charliechenmd.com · •••1538
  • Beauty by Buford · Lone Tree, United StatesContact c•••@kerloresearch.com→k•••@kerloresearch.com
  • H/K/B Surgery · Huntersville, United StatesContact e•••@hkbsurgery.com · •••2529→D•••@hkbsurgery.com · •••2529
  • The Plastics Clinic · Draper, United StatesContact k•••@theplasticsclinic.com · •••5557→x•••@theplasticsclinic.com · •••3228
  • Allen Gabriel MD · Vancouver, United StatesContact m•••@allengabrielmd.com→O•••@allengabrielmd.com
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Newport Plastic and Reconstructive Surgery Associates · Newport Beach, United StatesContact l•••@newportplastic.com · •••1502→c•••@newportplastic.com · •••1502
    • Charlie Chen MD., Corp · San Diego, United StatesContact b•••@me.com · •••1538→i•••@charliechenmd.com · •••1538
    • Beauty by Buford · Lone Tree, United StatesContact c•••@kerloresearch.com→k•••@kerloresearch.com
    • H/K/B Surgery · Huntersville, United StatesContact e•••@hkbsurgery.com · •••2529→D•••@hkbsurgery.com · •••2529
    • The Plastics Clinic · Draper, United StatesContact k•••@theplasticsclinic.com · •••5557→x•••@theplasticsclinic.com · •••3228
    • Allen Gabriel MD · Vancouver, United StatesContact m•••@allengabrielmd.com→O•••@allengabrielmd.com

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05945329
Lead sponsor
C. R. Bard
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Dec 12, 2024
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

Niccole Diaz
Contact
Niccole.Diaz@bd.com
407-694-0553
Jenna Baccari
Contact
jenna.baccari@bd.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion